Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2023-03-22 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-03-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text indicates it is a short filing (3513 characters) reporting the issuance of a press release dated March 13, 2023, furnished as an exhibit. There is no substantive financial data or detailed report content included, only a notification of an event and a press release. According to the rules, such short filings that announce or furnish a report or press release without containing the report itself should be classified as Regulatory Filings (RNS).
2023-03-13 English
FORM 10-Q
Interim / Quarterly Report Q2 2023
2023-03-09 English
FORM 10-Q
Interim / Quarterly Report Q1 2023
2023-03-07 English
FORM 10-K
Annual Report FY 2022
2023-02-27 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate changes. The content includes amendments to convertible promissory notes, a security agreement, and a notice from Nasdaq regarding non-compliance with listing rules and potential delisting. It also references a press release and exhibits related to these agreements. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document primarily announces financing amendments and a delisting notice. Given the detailed description of amendments to promissory notes and security agreements, this fits best under Capital/Financing Update (CAP). The delisting notice is mentioned but is not the primary focus, and the document is not solely a delisting announcement. Therefore, the classification is CAP with high confidence.
2023-02-23 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.